Every dementia journey is unique — but large studies now show clear patterns. Age, type of dementia, and general health all play major roles in how long a person lives after diagnosis.
New research shows that “time poverty” — not just poor habits — may quietly raise your dementia risk.
A major study finds up to 13% of people diagnosed with dementia may actually have a treatable liver-brain disorder called hepatic encephalopathy. The discovery could change how doctors and families approach memory loss in older adults.
A simple blood test was newly approved, replacing spinal taps and brain scans for ruling out Alzheimer’s. The FDA has just cleared Roche’s Elecsys® pTau181 — the first test shown to rule out Alzheimer’s with 98% accuracy, offering peace of mind and earlier answers for millions.
The biggest-ever study of genetic and observational data now suggests no safe level of alcohol when it comes to dementia risk. Could even “light drinking” be harmful?
IMAGINE THIS: Instead of going to an infusion center for treatment, you can switch to a weekly injection at home. That’s now a reality for many Alzheimer’s patients.
Simple, low-cost lifestyle changes can significantly slow or prevent cognitive decline. New research offers hope for families, caregivers, and anyone invested in brain health.
Women face a higher risk of Alzheimer’s. New research shows that low omega-3 levels may be a hidden factor—and boosting intake through diet or supplements could offer protection.
Caring for someone with Alzheimer’s is demanding enough. Now, instead of traveling for hours of infusions, families can turn to Leqembi IQLIK—a once-weekly injection approved by the FDA that makes treatment simpler, safer, and closer to home.
So many people wait years for a dementia diagnosis—long after symptoms begin. Why? And what can we do about it now?
Trontinemab, an experimental drug developed by Roche, has sparked excitement in large trials for slowing Alzheimer's faster and safer than anything before.
Leqembi, the first Alzheimer's-modifying drug, is a giant step forward—but how many people are getting it, and what does it really cost the average American? We dig into the numbers, the barriers, and the path forward.
